will increase by 25%. The total costs of HF are significant: the current estimate of $32 billion is expected to increase nearly 120% to $70 billion by 2030. 11 Using available immigration trends and existing prevalence rates, 1 conservative estimate places the number of Chagas cardiomyopathy (CCM) cases in the United States at 30 000 to 45 000. 12 These prevalence estimates, combined with available cost information for HF, imply a total cost of at least $200 to $300 million for CCM in the United States.
Despite a growing appreciation for CD in the United States, the burden of disease remains poorly defined. 13 The purpose of this study is to estimate the prevalence and impact of CD in a population of Latin American immigrants diagnosed with nonischemic cardiomyopathy in a Los Angeles county hospital. On the basis of previous studies, we hypothesized that CCM would be associated with increased mortality and hospitalization compared with non-CCM.
Methods

Ethics Statement
This study was approved by the Institutional Review Board of the Olive View-UCLA Education and Research Institute. All participants provided written informed consent before study enrollment.
Study Location
Olive View-UCLA Medical center is a 377-bed Los Angeles county hospital, which serves a population of 1 584 000 adults (≥18) covering 1123 m 2 . This population is 43% white, 38% Latino, 14% Asian, 3% black, and 2% other. Thirty-one percent of adults have an income of <200% of the federal poverty level, and 28% of residents (aged 18-64 years) are uninsured all or part of the year. These statistics were not significantly different when compared with the entire population of Los Angeles County. 14 
Study Population
All Latin American immigrant patients with newly diagnosed nonischemic cardiomyopathy at Olive View-UCLA Medical center were asked to participate in this study. From May 2007 to October 2011, 135 patients were prospectively enrolled into the study and followed until June 2012. Inclusion criteria were cardiomyopathy with left ventricular ejection fraction (LVEF) of ≤40% as documented by either echocardiography, gated single-photon emission computed tomography, or left ventriculography during cardiac catheterization, aged ≥18 years, and previous residence in Latin America (Mexico, Central, and South America) for at least 1 year. Exclusion criteria were coronary artery disease (evidence of ischemia or infarct on noninvasive stress testing or >70% stenosis on coronary angiography), severe valvular disease, history of any substance abuse, thyroid disease, severe uncontrolled hypertension, or a history of uncontrolled tachyarrhythmias. There was no compensation for participation. No information was collected on individuals who refused to participate, although only 1 individual refused to participate. Once enrolled, no participant was lost to follow-up or withdrew from the study.
Demographic Variables
At the time of study enrollment, participants were interviewed to assess basic demographic information, previous and current living situations, medical history, and current medication use. Because of low counts, response categories for country of origin were collapsed into 4 categories: Mexico, El Salvador, Guatemala, and other (Honduras, Nicaragua, Argentina, and Colombia). Similarly, response categories for type of Latin American house were collapsed into 3 categories: concrete, adobe, and other (brick, thatched, and wood).
Objective Data
At the time of study enrollment, all patients underwent a standard 12lead ECG and transthoracic echocardiogram. Electrocardiographic abnormalities were classified according to the Minnesota Code Manual of Electrocardiographic Findings. 15 Echocardiography was used to determine LVEF by visual estimation and left ventricular enddiastolic diameter (LVEDD) from the standard parasternal long axis view. 16 ECGs and echocardiograms were interpreted by 2 board-certified cardiologists blinded to the study; discrepancies were resolved by a third board-certified cardiologist with consensus opinion.
Diagnosis of CD
Serological testing was performed on study enrollment by the Centers for Disease Control and Prevention, Parasitic Diseases Laboratory using immunofluorescence assay, and ELISA (Chagatest ELISA recombinate v. 3.0; Wiener Laboratorios, Rosario, Argentina) tests. Participants were considered seropositive only if both the tests were positive.
End Points
The primary end point was all-cause mortality or heart transplantation. Death or heart transplantation was confirmed by reviewing medical records, contacting patients/family members, and accessing social security databases. The secondary end point was HF-related hospitalization. HF-related hospitalizations were confirmed by reviewing medical records or contacting patients/family members. For the purposes of this study, the diagnosis of HF was made when the terms CHF, CHF exacerbation, and fluid/volume overload were documented as discharge diagnoses on the discharge summary. One investigator with a medical background ascertained and interpreted the information about end points with the assistance of nonmedical study personnel. The time from study enrollment until the primary or secondary end points occurred was used for survival analysis.
Statistical Analysis
Categorical variable frequencies and proportions (%) are reported, whereas continuous variables are reported with medians and quartiles (25%, 75%). The P value for comparing baseline differences was determined by the Fisher exact test for categorical data or Wilcoxon rank-sum test for continuous data.
Survival curves for the primary and secondary end points were estimated by the Kaplan-Meier method, and the P values for differences in survival curves between groups were computed by the logrank test. The crude mortality rate is the number of deaths for all patients in that group divided by the total number of person-months of follow-up for all patients in that group. The crude hospitalization rate is similar, with the numerator representing the total number of hospitalizations for that group.
Univariate Cox proportional-hazard models were used to compute the hazard rate ratio for comparing time-dependent primary and secondary end point event rates between groups. The proportional hazard assumption was examined in all Cox models using the Supremum test. There was no evidence that the proportional hazard assumption was violated. There were insufficient events to perform valid multivariate Cox proportional-hazard models. All P values are 2-sided, with P<0.05 considered significant for all analyses. Analyses were conducted with SAS software, version 9.4 (SAS Inc, Cary, NC).
Results
A total of 135 participants were followed for a median of 43 months (3.6 years), with CD diagnosed in 25 (19%) patients. The baseline characteristics of the study population are shown in Table 1 , categorized by the presence or absence of CD. As a group, 57% of participants were men. The median age of the overall group was 57 years. The prevalence of September 2015 CCM, in decreasing order, was 38% for El Salvador, 25% for Guatemala, and 8% for Mexico. There were no differences in location (rural versus urban) or type of house (concrete, adobe, or other) among the CCM or non-CCM groups; however, those with CCM spent more time in their native country (41 versus 26 years; P=0.002) and less time in the United States (13 versus 24 years, P=0.01). Clinical variables such as the prevalence of hypertension, hyperlipidemia, tobacco use, and alcohol use were not clinically or significantly different between CCM and non-CCM groups, but diabetes mellitus was less prevalent in the CCM group (4% versus 34%; P=0.002). Therapeutic variables, including the use of β-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, aldosterone-antagonists, or HMG-CoA reductase inhibitors (statins), were no different between CCM and non-CCM groups, but amiodarone (40% versus 6%; P<0.001) and implantable cardioverter-defibrillator use (36% versus 7%; P=0.001) was more common in the CCM group.
Electrocardiographic and echocardiographic characteristics of the study group are shown in Table 2 . The presence of right-bundle branch block (20% versus 1%; P<0.001) was more common in the CCM group, but all other electrocardiographic variables were similar between the 2 groups. As a study group, the mean LVEDD was mildly dilated at 62 mm, whereas the median LVEF was severely depressed at 25%. There were no differences in LVEDD or LVEF among CCM or non-CCM groups. Table 3 displays the results of the unadjusted crude outcomes. All-cause mortality or heart transplantation occurred in 9 patients (36%) in the CCM group and in 11 patients (10%) in the non-CCM group (hazard ratio [HR], 4.46; 95% confidence interval, 1.8-10.8; P=0.001). The primary end point Figure 1 .
Discussion
This is the first and largest prospective study of patients with CCM in the United States. We followed a group of 135 Latin American immigrants diagnosed with advanced nonischemic cardiomyopathy (median LVEF, 25%) at a Los Angeles county hospital for a median of 43 months. CD was diagnosed by positive immunofluorescence assay and ELISA tests in 25 patients, yielding a 19% prevalence of advanced CCM (at least intermediate risk by the Rassi criteria 17 ). This prevalence estimate is similar to the 13% prevalence found in a smaller study of Latin American immigrants diagnosed with dilated cardiomyopathy in New York City. 18 This finding cannot be emphasized enough because multiple investigators have documented an increased mortality among patients with various stages of CCM when compared with those with non-CCM. Our data corroborate these findings, as CCM was associated with a primary end point of mortality or heart transplantation that was 4.46× higher than non-CCM ( Figure 1A) , despite similar LVEDD and LVEF. This HR estimate is in accordance with previous estimates of 3.29 to 6.09 for CCM-related mortality. [19] [20] [21] In addition to increased mortality/heart transplantation, our study demonstrated an increased burden of HF-related hospitalization in patients with CCM. HF-related hospitalization was 2.22× higher in CCM compared with non-CCM ( Figure 1B) , despite similar LVEDD and LVEF. These findings are of paramount importance in the era of Medicare's Hospital Readmission Reduction Program, in which hospital admissions and readmissions for HF are increasingly scrutinized and tied to reimbursement. 22 Our study provides the first insight into HF-related hospitalization for CCM in a US population.
Identifying CD in a patient with cardiomyopathy not only helps with prognostication but also aids in clinical treatment decisions. For instance, the antiarrhythmic amiodarone has been shown to have direct anti-T cruzi effects by disrupting calcium homeostasis in vitro, 23 with a case report of decreased parasitemia and improved LVEF. 24, 25 Our center uses amiodarone liberally in patients with CCM, thus explaining the significant difference in amiodarone use observed in our study between the CCM and non-CCM groups (40% versus 6%; P<0.001). The high burden of malignant ventricular arrhythmias, which can involve the epicardium, right ventricle, or apical aneurysm, are important considerations when contemplating implantable cardioverter-defibrillator therapy or radiofrequency ablation in patients with CD. [26] [27] [28] [29] Finally, it is now recognized that survival in patients with CCM after heart transplant may be better than those patients with other forms of nonischemic cardiomyopathy; however, reactivation rates as high as 26.5% to 42.9% have been reported and require a unique post-transplant surveillance process to monitor for reactivation and provide prompt antiparasitic treatment. 30, 31 Many baseline characteristics were found to be associated with CD in this study. Although the majority of participants originated from Mexico (53%), those diagnosed with CCM were predominantly from El Salvador (54%). These findings may be because of sampling error as the heterogeneous geographical distribution of CD in Mexico makes it possible that the Mexican immigrants included in our study were not from highly endemic areas within Mexico. 32, 33 However, 1 small study of patients with Chagas heart disease in Los Angeles also reported the highest prevalence among those from El Salvador. 8 The fact that El Salvador has the highest prevalence of CD in Central America likely also plays a role in these findings. 2 We also found that participants who lived in their native country longer were more likely to have acquired CD, presumably because of increased exposure to the causative agent. Finally, the finding of right-bundle branch block on EKG was associated with CCM as has been previously reported. 2 Despite our prospective cohort of patients with CCM representing the largest in the United States, one of the major limitations of our study was the small sample size. Because CD is not endemic to the United States, our sample of CCM was relatively small compared with similar studies conducted in Brazil, which have study populations of CCM exceeding 200 patients. [19] [20] [21] However, as our entire CCM cohort originated from Mexico, El Salvador, or Guatemala, this cohort represents an area of Latin America not previously studied with respect to risk factors and outcomes. Furthermore, Central America and Brazil are populated with different strains of T cruzi, which may affect the virulence and clinical course of CD. 2, 34, 35 Another limitation of the study is the assumption that seropositivity for CD meant that the parasitic infection had caused cardiomyopathy. To address this issue, we excluded patients with other known causes of nonischemic cardiomyopathy. Because it is entirely possible that CD and another cause of nonischemic cardiomyopathy may coexist in the same person, the prevalence of CD in our study group may not accurately reflect the true prevalence of CCM among Latin American patients with cardiomyopathy in Los Angeles. Moreover, because only advanced cases of CCM were enrolled in this study, our results should not be misconstrued to represent outcomes of all patients with CD. Previous research has shown that seropositivity for CD with little or no cardiac involvement is associated with a more indolent disease course. 2, 17 In conclusion, this is the first and largest prospective study following a group of Latin American immigrants with CCM in the United States. Although somewhat limited by sample size, the data suggest that ≈1 in 5 Latin American immigrants in Los Angeles with nonischemic cardiomyopathy may have CD. Immigrants from El Salvador and those who have lived in their native country >40 years were more likely to have CCM. Survival analysis showed that advanced CCM is clearly associated with increased mortality/heart transplantation and hospitalization compared with non-CCM, despite similar LVEDD and LVEF. On the basis of the results of this and other studies, healthcare facilities providing care for Latin American immigrants diagnosed with nonischemic cardiomyopathy in the United States should consider evaluating for CD as a possible cause of cardiomyopathy. 18 
